23-LB: Overexpression of microRNA-16 Derepresses the Mitochondrial Function to Exacerbate Cardiomyopathy in Streptozotocin-Induced Diabetic Mice
Jing Zhou, Yinghong Zhu, Jing Fan
Abstract
Jing Zhou, Yinghong Zhu, Jing Fan
Abstract
Introduction: Diabetic cardiomyopathy is initially characterized by myocardial fibrosis, dysfunctional remodeling, and associated diastolic dysfunction, later by systolic dysfunction, and eventually by clinical heart failure. MicroRNAs (miRNAs), the endogenous small non-coding RNAs, were recognized to play significant roles in diabetes. But, it remains unknown whether mitochondrial function is modulated by miRNAs during diabetic cardiomyopathy. Aim: This study investigates the potential role of microRNA-16 (miR-16) in modulating mitochondrial function during diabetic cardiomyopathy. Methods and Results: To assess the function of miR-16 in vivo, miR-16 was expressed using a adeno-associated virus serotype 9 (AAV9) viral vector in male 1-week-old mice C57BL/6J mice. At 6-week-old, these mice received three consecutive daily i.p. injections of STZ (55 mg/kg body weight) combined with 18 weeks of high-fat diet to induce T2DM. We demonstrated that miR-16 expression was slight increased in diabetic mice. Overexpression of miR-16 exacerbated diabetic cardiomyopathy which reflected by increasing myocardial fibrosis and displaying a diastolic dysfunction in STZ-induced mice. Impaired mitochondrial function was observed in electron microscopy of myocardium in mice with overexpression of miR-16. In vitro, high glucose (HG) treated cultured cardiomyocytes with overexpression miR-16 showed a worse mitochondrial damage, and inhibition of miR-16 induced a protective effects role in HG-treated cardiomyocytes. Molecular mechanisms linked to the underlying pathophysiological changes include abnormalities in AMP-activated protein kinase, p38 MAPK and PGC1α. Conclusions: In conclusion, our results show that miR-16 plays an important role in the development of diabetic cardiomyopathy in T2DM mice, which can be targeted for therapeutic intervention. Disclosure J. Zhou: None. Y. Zhu: None. J. Fan: None.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Introduction: Diabetic cardiomyopathy is initially characterized by myocardial fibrosis, dysfunctional remodeling, and associated diastolic dysfunction, later by systolic dysfunction, and eventually by clinical heart failure. MicroRNAs (miRNAs), the endogenous small non-coding RNAs, were recognized to play significant roles in diabetes. But, it remains unknown whether mitochondrial function is modulated by miRNAs during diabetic cardiomyopathy. Aim: This study investigates the potential role of microRNA-16 (miR-16) in modulating mitochondrial function during diabetic cardiomyopathy. Methods and Results: To assess the function of miR-16 in vivo, miR-16 was expressed using a adeno-associated virus serotype 9 (AAV9) viral vector in male 1-week-old mice C57BL/6J mice. At 6-week-old, these mice received three consecutive daily i.p. injections of STZ (55 mg/kg body weight) combined with 18 weeks of high-fat diet to induce T2DM. We demonstrated that miR-16 expression was slight increased in diabetic mice. Overexpression of miR-16 exacerbated diabetic cardiomyopathy which reflected by increasing myocardial fibrosis and displaying a diastolic dysfunction in STZ-induced mice. Impaired mitochondrial function was observed in electron microscopy of myocardium in mice with overexpression of miR-16. In vitro, high glucose (HG) treated cultured cardiomyocytes with overexpression miR-16 showed a worse mitochondrial damage, and inhibition of miR-16 induced a protective effects role in HG-treated cardiomyocytes. Molecular mechanisms linked to the underlying pathophysiological changes include abnormalities in AMP-activated protein kinase, p38 MAPK and PGC1α. Conclusions: In conclusion, our results show that miR-16 plays an important role in the development of diabetic cardiomyopathy in T2DM mice, which can be targeted for therapeutic intervention. Disclosure J. Zhou: None. Y. Zhu: None. J. Fan: None.
Key concepts: Diabetic cardiomyopathy, Cardiomyopathy, Streptozotocin, Internal medicine, Endocrinology, Cardiac function curve, Medicine, Diabetes mellitus